prednisolone has been researched along with Opportunistic Infections in 100 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-four patients with collagen diseases suffering from onychomycosis were treated with fluconazole and showed remarkable improvement." | 9.08 | [Effects of fluconazole on onychomycosis in the patients with collagen diseases]. ( Iwamoto, I; Izumi, H; Nawata, Y; Otawa, M; Sueishi, M; Sugiyama, T; Sumida, T; Takabayashi, K; Tanabe, E; Tomioka, H, 1995) |
| "A 78-year-old woman with rheumatoid arthritis on TNF-α inhibitor, methotrexate and prednisolone presented with severe but unspecific symptoms such as leg weakness, shivering, bifrontal headache, nausea and staggering." | 7.96 | [Neurological symptoms in a patient on anti-TNF therapy, methotrexate and prednisolone for rheumatoid arthritis]. ( Bach, M; Baerwald, C; Schob, S, 2020) |
| "Thirty-four patients with collagen diseases suffering from onychomycosis were treated with fluconazole and showed remarkable improvement." | 5.08 | [Effects of fluconazole on onychomycosis in the patients with collagen diseases]. ( Iwamoto, I; Izumi, H; Nawata, Y; Otawa, M; Sueishi, M; Sugiyama, T; Sumida, T; Takabayashi, K; Tanabe, E; Tomioka, H, 1995) |
| "A 70-year-old man treated for 6 months with prednisolone for nephrotic syndrome, was referred to our pulmonary division because of a nodule in the right lower lung field." | 4.81 | [Pulmonary nocardiosis associated with nephrotic syndrome]. ( Kawamura, T; Mochizuki, Y; Nakahara, Y; Sasaki, S; Tanaka, A; Watanabe, S; Yuugetu, H, 2001) |
| "A 78-year-old woman with rheumatoid arthritis on TNF-α inhibitor, methotrexate and prednisolone presented with severe but unspecific symptoms such as leg weakness, shivering, bifrontal headache, nausea and staggering." | 3.96 | [Neurological symptoms in a patient on anti-TNF therapy, methotrexate and prednisolone for rheumatoid arthritis]. ( Bach, M; Baerwald, C; Schob, S, 2020) |
| "We present a case of acute upper gastrointestinal haemorrhage in a patient with systemic vasculitis immunosuppressed on cyclophosphamide and prednisolone." | 3.81 | Catastrophic gastrointestinal complication of systemic immunosuppression. ( Gangopadhyay, M; Gaya, DR; Smith, LA, 2015) |
| " The diagnosis of acquired hemophilia A (AHA) was made, and treatment with prednisolone (PSL) was started." | 3.75 | [Acquired hemophilia complicated with multiple muscle abscess by Nocardia]. ( Abe, T; Azuma, T; Fujiwara, H; Hato, T; Narumi, H; Yakushijin, Y; Yamanouchi, J; Yasukawa, M, 2009) |
| "A 78-year-old man administered prednisolone and cyclosporin A for bullous pemphigoid and found in computed tomography (CT) to have a left-lung nodule was suspected of having a fungal infection due to elevated blood (1-->3)-beta-D-glucan." | 3.75 | [A case of disseminated nocardiosis followed by pneumocystis pneumonia in a patient prescribed corticosteroid and cyclosporin A and having elevated blood (1-->3)-beta-D-glucan]. ( Harada, S; Hatakeyama, S; Itoyama, S; Kitazawa, T; Koike, K; Ota, Y, 2009) |
| " We report a case of a 61-year-old man with seronegative rheumatoid arthritis and fibrosing alveolitis on long-term prednisolone who presented with a number of tender, red, subcutaneous nodules on his upper arms and a pustule on his left cheek." | 3.72 | Disseminated cutaneous infection with Mycobacterium chelonae in a patient with steroid-dependent rheumatoid arthritis. ( Lamb, SR; Merchant, W; Stables, GI, 2004) |
| " The infection coincided with neutropenia resulting from pyrazolone treatment." | 3.67 | Trichosporon beigelii pneumonia in a neutropenic patient. ( Borras, R; Chiner, E; Franco, J; Marin, J, 1989) |
| "Patients with rheumatoid arthritis are at higher risk for serious infections and death from infection than the general public." | 2.48 | Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. ( Winthrop, KL, 2012) |
| "A 56-year-old Japanese man with ulcerative colitis and a history of Sweet's syndrome who was taking prednisolone and azathioprine presented with a moderate exacerbation of ulcerative colitis, abdominal pain, diarrhea, and bloody stools along with cytomegalovirus infection." | 1.91 | Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report. ( Ichimori, T; Ishikawa, Y; Nagano, S; Oki, Y; Uchida, K; Yamada, T, 2023) |
| "High rates of varicella screening and immunisation within a PIBD population are possible, resulting in a reduction in hospital admissions for varicella treatment." | 1.56 | A Decade of Varicella Screening Within a Paediatric Inflammatory Bowel Disease Population. ( Al-Hourani, G; Armstrong, L; Barclay, AR; Curtis, L; Delahunty, C; Eccleston, A; Flynn, DM; Garrick, V; Gervais, L; Hansen, R; Harris, RE; Hegde, V; Merrick, V; Russell, RK; Tayler, R, 2020) |
| " Preventative measures are not usually required in patients who receive a short high-dosed treatment (30 mg PED in 7 days) or prednisolone at a dosage of < 15 mg/day." | 1.48 | [Infections during glucocorticoid use]. ( den Hoed, CM; Minderhoud, TC; Schurink, CAM; van Daele, PLA; van Meer, MPA; van Thiel, RJ, 2018) |
| " We investigated whether high-dose MZR is effective and safe for renal transplant patients in conjunction with cyclosporine (CsA), basiliximab, and corticosteroids." | 1.43 | Efficacy and Safety of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplantation: A Japanese Multicenter Study. ( Akioka, K; Fujisawa, M; Fukuda, Y; Horimi, T; Ito, SI; Nakatani, T; Nishimura, K; Sugitani, A; Uchida, K; Ushigome, H; Yoshimura, N; Yuzawa, K, 2016) |
| "There are reports on patients with systemic lupus erythematosus (SLE) with aspergillosis; however, aspergillosis-related pneumothorax has not been reported in SLE." | 1.40 | The development of pulmonary aspergillosis and pneumothorax in a patient with neutropenic systemic lupus erythematosus and successful treatment of the first case. ( Barutcu, E; Celik, AD; Pamuk, GE; Pamuk, ON, 2014) |
| "Mucormycosis is a devastating fungal infection commonly seen in immunocompromised individuals, including those with NHL, but it is affecting the same region has been reported very rarely." | 1.38 | T cell non-Hodgkin's lymphoma with colesional mucormycosis presenting as palatal perforation: a case report. ( Agarwal, PK; Aggarwal, S; Dhawan, S; Garg, A; Khan, AA; Siraj, F, 2012) |
| "Patient was started on NIH protocol for lupus nephritis on which he was doing well." | 1.37 | Young male with systemic lupus erythematosus presenting with sensorineural deafness with immune suppression induced miliary tuberculosis. ( Chatterjee, S; Ghosh, A; Kundu, S; Mitra, R, 2011) |
| "Compared to SLE without PCP, those with PCP infection have significantly higher activity index by MEX-SLEDAI (13." | 1.35 | Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. ( Janwityanujit, S; Lertnawapan, R; Nantiruj, K; Totemchokchyakarn, K, 2009) |
| "Pulmonary nocardiosis was clinically suspected because we detected nocardia from Gram staining of sputum." | 1.34 | [A case of pulmonary nocardiosis cured by early sulfamethoxazole-trimethoprim therapy]. ( Katakura, H; Kojima, M; Matsui, Y; Sakai, N; Wada, H; Yamanaka, A, 2007) |
| "Brain MRI revealed multiple brain abscesses at more than 20 sites." | 1.33 | [Pulmonary nocardiosis complicated with multiple brain abscess]. ( Aida, S; Kanoh, S; Kobayashi, H; Motoyoshi, K; Shimokawaji, T, 2005) |
| "Gas gangrene is extremely rare in patients with ulcerative colitis or Crohn's disease and immunosuppression." | 1.33 | [Gas gangrene with ulcerative colitis under immunosuppressive therapy: report of a case]. ( Freitag, M; Jackisch, T; Ludwig, K, 2006) |
| " Although corticosteroid therapy has been reported to be effective in some CCE patients, the indications of steroid therapy, dosage of corticosteroids, duration of the treatment, or efficacy of prophylactic administration of antibiotics are not yet established." | 1.33 | [Pulmonary infection of Pneumocystis carinii and Cytomegalo virus in the treatment of cholesterol crystal embolism]. ( Fujii, M; Fujita, Y; Kitamura, H; Matsui, I; Okuno, A; Yamamoto, R, 2006) |
| "In early pulmonary alveolar proteinosis with focal opacity, HRCT can demonstrate the substantial findings of alveolar proteinosis such as a crazy-paving appearance or geographic distribution." | 1.33 | [Radiological findings in initial pulmonary alveolar proteinosis detected in the post-treatment course of nocardiosis]. ( Aida, S; Kanoh, S; Kobayashi, H; Motoyoshi, K; Sugimoto, C, 2006) |
| "The occurrence of opportunistic infections is not rare during the treatment of connective tissue diseases, including dermatomyositis because of the patient's immunosuppression." | 1.33 | Cytomegalovirus infection complicating immunosuppressive therapy for dermatomyositis. ( Aiba, S; Hashimoto, A; Okuyama, R; Tagami, H; Watanabe, H, 2006) |
| "We present the case of a patient with Crohn's disease under immunosuppressive therapy who developed a spontaneous covered spleen rupture in the course of a septic shock with DIG due to a Varizella zoster infection." | 1.32 | [Functional asplenia after severe varicella zoster-infection diagnosis by colour Doppler ultrasound]. ( Arnold, R; Diedrich, J; Eissele, R; Görg, C, 2003) |
| "Patients with systemic lupus erythematosus (SLE) are usually exposed to high doses of corticosteroids and eventually develop defective cellular immunity that increases the risk for active tuberculosis." | 1.32 | An overwhelming pulmonary fungus ball in a systemic lupus erythematosus patient. ( Boztosun, Y; Kiris, A; Kocakoc, E; Ozcakar, L; Ozgocmen, S; Yildirim, N, 2003) |
| "Pulmonary nocardiosis is difficult to diagnose and should be considered in the differential diagnosis, especially in an immunocompromised host." | 1.31 | Pulmonary nocardiosis in a patient treated with corticosteroid therapy. ( Endoh, S; Kasai, T; Narushima, M; Ohtsuka, H; Suzuki, H; Tomita, S; Tsuzura, Y; Yamada, M, 2002) |
| "The history revealed an anaplastic anemia." | 1.29 | [Mycotic retrobulbar neuritis]. ( Kössling, S; Meier, P; Nenning, H; Penk, A, 1994) |
| "Prednisolone alone was the most effective on minimal change NS in the elderly." | 1.29 | Nephrotic syndrome in the elderly--clinicopathological study. ( Hara, K; Harada, T; Ozono, Y; Taguchi, T; Taura, K; Yamaguchi, K, 1994) |
| "The possibility of nocardiosis should be considered in the differential diagnosis of such patients." | 1.29 | Disseminated subcutaneous Nocardia asteroides abscesses in a patient after bone marrow transplantation. ( Fujiyama, Y; Hiramitu, Y; Hodohara, K; Hosoda, S; Kitoh, K; Sugiura, H; Sumiyoshi, K, 1993) |
| "Children with malignancy have a high incidence of pneumonia and pneumonitis and death is rare if the patient does not have terminal malignant disease." | 1.28 | Pneumonia and pneumonitis in childhood malignancy. ( Eden, OB; Elton, R; Shaw, NJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (6.00) | 18.7374 |
| 1990's | 21 (21.00) | 18.2507 |
| 2000's | 48 (48.00) | 29.6817 |
| 2010's | 19 (19.00) | 24.3611 |
| 2020's | 6 (6.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oki, Y | 1 |
| Nagano, S | 1 |
| Ishikawa, Y | 1 |
| Yamada, T | 1 |
| Ichimori, T | 1 |
| Uchida, K | 2 |
| Harris, RE | 1 |
| Curtis, L | 1 |
| Hegde, V | 1 |
| Garrick, V | 1 |
| Gervais, L | 1 |
| Armstrong, L | 1 |
| Delahunty, C | 1 |
| Eccleston, A | 1 |
| Al-Hourani, G | 1 |
| Flynn, DM | 1 |
| Merrick, V | 1 |
| Barclay, AR | 1 |
| Tayler, R | 1 |
| Hansen, R | 1 |
| Russell, RK | 1 |
| Kimura, R | 1 |
| Yamada, N | 1 |
| Yoshida, Y | 1 |
| Ito, A | 1 |
| Horie, T | 1 |
| Anzawa, K | 1 |
| Mochizuki, T | 1 |
| Yamamoto, O | 1 |
| Bach, M | 1 |
| Schob, S | 1 |
| Baerwald, C | 1 |
| Phanish, MK | 1 |
| Hull, RP | 1 |
| Andrews, PA | 1 |
| Popoola, J | 1 |
| Kingdon, EJ | 1 |
| MacPhee, IAM | 1 |
| Larroquette, M | 1 |
| Issa, N | 1 |
| Gabriel, F | 1 |
| Camou, F | 1 |
| Terayama, Y | 1 |
| Matsuura, T | 1 |
| Ozaki, K | 1 |
| Minderhoud, TC | 1 |
| van Meer, MPA | 1 |
| van Thiel, RJ | 1 |
| den Hoed, CM | 1 |
| van Daele, PLA | 1 |
| Schurink, CAM | 1 |
| Kniazev, OV | 1 |
| Lazebnik, LB | 1 |
| Parfenov, AI | 1 |
| Ruchkina, IN | 1 |
| Shcherbakov, PL | 1 |
| Konopliannikov, AG | 1 |
| Mikhaĭlova, ZF | 1 |
| Khomeriki, SG | 1 |
| Khan, AA | 1 |
| Garg, A | 1 |
| Dhawan, S | 1 |
| Agarwal, PK | 1 |
| Siraj, F | 1 |
| Aggarwal, S | 1 |
| Ohyama, Y | 1 |
| Kumode, T | 1 |
| Eguchi, G | 1 |
| Yamaguchi, T | 1 |
| Maeda, Y | 1 |
| Sumida, K | 1 |
| Ubara, Y | 1 |
| Muso, E | 1 |
| Katagiri, S | 1 |
| Yoshizawa, S | 1 |
| Gotoh, M | 1 |
| Nakamura, I | 1 |
| Ohyashiki, K | 1 |
| Pamuk, ON | 1 |
| Pamuk, GE | 1 |
| Barutcu, E | 1 |
| Celik, AD | 1 |
| Smith, LA | 1 |
| Gangopadhyay, M | 1 |
| Gaya, DR | 1 |
| Cartron, G | 1 |
| Hourcade-Potelleret, F | 1 |
| Morschhauser, F | 1 |
| Salles, G | 1 |
| Wenger, M | 1 |
| Truppel-Hartmann, A | 1 |
| Carlile, DJ | 1 |
| Ushigome, H | 1 |
| Nishimura, K | 1 |
| Akioka, K | 1 |
| Fukuda, Y | 1 |
| Yuzawa, K | 1 |
| Fujisawa, M | 1 |
| Sugitani, A | 1 |
| Ito, SI | 1 |
| Nakatani, T | 1 |
| Horimi, T | 1 |
| Yoshimura, N | 1 |
| Tourret, J | 1 |
| Willing, BP | 1 |
| Dion, S | 1 |
| MacPherson, J | 1 |
| Denamur, E | 1 |
| Finlay, BB | 1 |
| Lertnawapan, R | 1 |
| Totemchokchyakarn, K | 1 |
| Nantiruj, K | 1 |
| Janwityanujit, S | 1 |
| Yamanouchi, J | 1 |
| Abe, T | 1 |
| Azuma, T | 1 |
| Narumi, H | 1 |
| Fujiwara, H | 1 |
| Yakushijin, Y | 1 |
| Hato, T | 1 |
| Yasukawa, M | 1 |
| Namdar, T | 1 |
| Mailänder, P | 1 |
| Lange, T | 1 |
| Harada, S | 1 |
| Hatakeyama, S | 1 |
| Kitazawa, T | 1 |
| Itoyama, S | 1 |
| Ota, Y | 1 |
| Koike, K | 1 |
| Kobashigawa, JA | 1 |
| Kiyosaki, KK | 1 |
| Patel, JK | 1 |
| Kittleson, MM | 1 |
| Kubak, BM | 1 |
| Davis, SN | 1 |
| Kawano, MA | 1 |
| Ardehali, AA | 1 |
| Kudo, T | 1 |
| Aoyagi, Y | 1 |
| Fujii, T | 1 |
| Ohtsuka, Y | 1 |
| Nagata, S | 1 |
| Shimizu, T | 2 |
| Böttcher, A | 1 |
| Guder, E | 1 |
| Just, T | 1 |
| Kundu, S | 1 |
| Mitra, R | 1 |
| Chatterjee, S | 1 |
| Ghosh, A | 1 |
| Sugiura, K | 1 |
| Sugiura, N | 1 |
| Yagi, T | 1 |
| Iguchi, M | 1 |
| Ohno, H | 1 |
| Miyazaki, Y | 1 |
| Akiyama, M | 1 |
| Winthrop, KL | 1 |
| Seta, N | 1 |
| Nawata, M | 1 |
| Wada, R | 1 |
| Mori, K | 1 |
| Sekigawa, I | 1 |
| Iida, N | 1 |
| Maeda, M | 1 |
| Hashimoto, H | 1 |
| Tanaka, H | 1 |
| Suzuki, K | 1 |
| Nakahata, T | 1 |
| Tateyama, T | 1 |
| Sugimoto, K | 1 |
| Ito, E | 1 |
| Waga, S | 1 |
| Cheng, CL | 1 |
| Song, KP | 1 |
| Chee, SP | 1 |
| Chan, TK | 1 |
| Diedrich, J | 1 |
| Görg, C | 1 |
| Eissele, R | 1 |
| Arnold, R | 1 |
| López-Duarte, M | 1 |
| Insunza, A | 1 |
| Conde, E | 1 |
| Iriondo, A | 1 |
| Mazorra, F | 1 |
| Zubizarreta, A | 1 |
| Kocakoc, E | 1 |
| Ozgocmen, S | 1 |
| Kiris, A | 1 |
| Ozcakar, L | 1 |
| Boztosun, Y | 1 |
| Yildirim, N | 1 |
| Akutsu, M | 1 |
| Fujioka, T | 1 |
| Kurihara, T | 1 |
| Oharasei, T | 1 |
| Takahashi, H | 1 |
| Lamb, SR | 1 |
| Stables, GI | 1 |
| Merchant, W | 1 |
| Takabayashi, K | 3 |
| Hanaoka, H | 1 |
| Kotanidou, AN | 1 |
| Zakynthinos, E | 1 |
| Andrianakis, I | 1 |
| Zervakis, D | 1 |
| Kokotsakis, I | 1 |
| Argyrakos, T | 1 |
| Argiropoulou, A | 1 |
| Margariti, G | 1 |
| Douzinas, E | 1 |
| Kubota, Y | 1 |
| Sano, M | 1 |
| Nakazato, S | 1 |
| Tsuneyoshi, N | 1 |
| Tomimasu, R | 1 |
| Kuwahara, N | 1 |
| Fukushima, N | 1 |
| Funai, N | 1 |
| Suga, K | 1 |
| Sueoka, E | 1 |
| Holtkamp, M | 1 |
| Okuducu, AF | 1 |
| Klingebiel, R | 1 |
| Ploner, CJ | 1 |
| Eisendle, K | 1 |
| Fritsch, P | 1 |
| Tanaka, Y | 3 |
| Takahashi, S | 1 |
| Takahashi, T | 1 |
| Kuragano, T | 1 |
| Nagura, Y | 1 |
| Fujita, T | 1 |
| Nakayama, T | 1 |
| Matsumoto, K | 1 |
| Iliopoulos, A | 1 |
| Kedikoglou, S | 1 |
| Laxanis, S | 1 |
| Kourouklis, S | 1 |
| Katsaros, E | 1 |
| Shimokawaji, T | 1 |
| Kobayashi, H | 2 |
| Kanoh, S | 2 |
| Motoyoshi, K | 2 |
| Aida, S | 2 |
| Kaşifoğlu, T | 1 |
| Korkmaz, C | 1 |
| Ozkan, R | 1 |
| Hirose, I | 1 |
| Ymamaguchi, H | 1 |
| Inaguma, D | 1 |
| Ono, K | 1 |
| Shimada, S | 1 |
| Kawada, J | 1 |
| Shiraki, K | 1 |
| Kimura, H | 1 |
| Kawakami, K | 1 |
| Ito, R | 1 |
| Watanabe, Y | 1 |
| Goto, T | 1 |
| Enomoto, T | 1 |
| Azuma, A | 1 |
| Matsumoto, A | 1 |
| Nei, T | 1 |
| Hiramatsu, K | 1 |
| Abe, S | 1 |
| Usuki, J | 1 |
| Kudoh, S | 1 |
| Jackisch, T | 1 |
| Freitag, M | 1 |
| Ludwig, K | 1 |
| Saito, K | 1 |
| Okuno, A | 1 |
| Yamamoto, R | 1 |
| Matsui, I | 1 |
| Kitamura, H | 1 |
| Fujita, Y | 1 |
| Fujii, M | 1 |
| Yang, CD | 1 |
| Wang, XD | 1 |
| Ye, S | 1 |
| Gu, YY | 1 |
| Bao, CD | 1 |
| Wang, Y | 1 |
| Chen, SL | 1 |
| Chen, HS | 1 |
| Tsai, WP | 1 |
| Leu, HS | 1 |
| Ho, HH | 1 |
| Liou, LB | 1 |
| Sugimoto, C | 1 |
| Ichiyasu, H | 1 |
| Yamamura, A | 1 |
| Honda, M | 1 |
| Okamoto, S | 1 |
| Tsumori, K | 1 |
| Okamoto, T | 1 |
| Sato, K | 1 |
| Matsumoto, M | 1 |
| Kohrogi, H | 1 |
| Hashimoto, A | 1 |
| Okuyama, R | 1 |
| Watanabe, H | 1 |
| Tagami, H | 1 |
| Aiba, S | 1 |
| Howman, R | 1 |
| Kulkarni, H | 1 |
| Lateef, A | 1 |
| Vasoo, S | 1 |
| Boey, ML | 1 |
| Wada, H | 1 |
| Sakai, N | 1 |
| Matsui, Y | 1 |
| Kojima, M | 1 |
| Katakura, H | 1 |
| Yamanaka, A | 1 |
| Maronn, ML | 1 |
| Corden, T | 1 |
| Drolet, BA | 1 |
| Hasselbach, HC | 1 |
| Fickenscher, H | 1 |
| Nölle, B | 1 |
| Roider, J | 1 |
| Nawata, Y | 1 |
| Sumida, T | 1 |
| Izumi, H | 1 |
| Otawa, M | 1 |
| Iwamoto, I | 1 |
| Tanabe, E | 1 |
| Tomioka, H | 2 |
| Sugiyama, T | 2 |
| Sueishi, M | 1 |
| Nenning, H | 1 |
| Meier, P | 1 |
| Penk, A | 1 |
| Kössling, S | 1 |
| Ozono, Y | 1 |
| Harada, T | 1 |
| Yamaguchi, K | 1 |
| Taura, K | 1 |
| Hara, K | 1 |
| Taguchi, T | 1 |
| Hodohara, K | 1 |
| Fujiyama, Y | 1 |
| Hiramitu, Y | 1 |
| Sumiyoshi, K | 1 |
| Kitoh, K | 1 |
| Hosoda, S | 1 |
| Sugiura, H | 1 |
| Morland, BJ | 1 |
| Shaw, PJ | 1 |
| Späth, M | 1 |
| Schollmeyer, P | 1 |
| Yanase, K | 1 |
| Nakamura, M | 1 |
| Toyoda, T | 1 |
| Dote, K | 1 |
| Tsunami, A | 1 |
| Hisaoka, N | 1 |
| Maruyama, T | 1 |
| Shikanai, K | 1 |
| Maruyama, S | 1 |
| Ueno, K | 1 |
| Machet, L | 1 |
| Jan, V | 1 |
| Machet, MC | 1 |
| Vaillant, L | 1 |
| Lorette, G | 1 |
| Teuber, G | 1 |
| Schwarting, A | 1 |
| Mildenberger, P | 1 |
| Schmidt-Brücken, G | 1 |
| Moll, R | 1 |
| Bornemann, A | 1 |
| Wandel, E | 1 |
| Wanitschke, R | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Khatchatourian, M | 1 |
| Seaton, TL | 1 |
| Schneider, T | 1 |
| Strupp, R | 1 |
| Kühnen, E | 1 |
| Jochem, C | 1 |
| Boesken, WH | 1 |
| Neumann, UP | 1 |
| Knoop, M | 1 |
| Lang, M | 1 |
| Bechstein, WO | 1 |
| Langrehr, JM | 1 |
| Raakow, R | 1 |
| Neuhaus, P | 1 |
| Veness, MJ | 1 |
| Tsang, KW | 1 |
| Lam, PS | 1 |
| Yuen, KY | 1 |
| Ooi, CC | 1 |
| Lam, W | 1 |
| Ip, M | 1 |
| Jamil, B | 1 |
| Nicholls, KM | 1 |
| Becker, GJ | 1 |
| Walker, RG | 1 |
| Kim, HC | 1 |
| Park, SB | 1 |
| Kim, HT | 1 |
| Cho, WH | 1 |
| Park, CH | 1 |
| Matsumori, A | 1 |
| Nishiya, K | 1 |
| Tahara, K | 1 |
| Yamasaki, H | 1 |
| Hashimoto, K | 1 |
| Mitsunaka, H | 1 |
| Tokuda, M | 1 |
| Takahara, J | 1 |
| Matoba, K | 1 |
| Miyawaki, S | 1 |
| Sekhar, U | 1 |
| Madan, M | 1 |
| Ranjitham, M | 1 |
| Abraham, G | 1 |
| Eapen, G | 1 |
| Ohashi, H | 1 |
| Ohno, R | 1 |
| Sadikot, RT | 1 |
| Doré, P | 1 |
| Arnold, AG | 1 |
| Remport, A | 1 |
| Sasvári, I | 1 |
| Toronyi, E | 1 |
| Borka, P | 1 |
| Lázár, N | 1 |
| Járay, J | 1 |
| Perner, F | 1 |
| Saito, T | 1 |
| Seo, S | 1 |
| Kanda, Y | 1 |
| Shoji, N | 1 |
| Ogasawara, T | 1 |
| Murakami, J | 1 |
| Tanosaki, R | 1 |
| Tobinai, K | 1 |
| Takaue, Y | 1 |
| Mineishi, S | 1 |
| Yuugetu, H | 1 |
| Mochizuki, Y | 1 |
| Nakahara, Y | 1 |
| Tanaka, A | 1 |
| Kawamura, T | 1 |
| Watanabe, S | 1 |
| Sasaki, S | 1 |
| Ohira, S | 1 |
| Isoda, K | 1 |
| Hamanaka, H | 1 |
| Takahashi, K | 1 |
| Nishimoto, K | 1 |
| Mizutani, H | 1 |
| Narushima, M | 1 |
| Suzuki, H | 1 |
| Kasai, T | 1 |
| Tsuzura, Y | 1 |
| Tomita, S | 1 |
| Endoh, S | 1 |
| Yamada, M | 1 |
| Ohtsuka, H | 1 |
| Shaw, NJ | 1 |
| Elton, R | 1 |
| Eden, OB | 1 |
| Waldmann, KD | 1 |
| Clerc, D | 1 |
| Brousse, C | 1 |
| Mariette, X | 1 |
| Bennet, P | 1 |
| Bisson, M | 1 |
| Crellin, AM | 1 |
| Shareef, DS | 1 |
| Maher, EJ | 1 |
| Scholz, D | 1 |
| Blank, W | 1 |
| Bärwolf, C | 1 |
| Ditscherlein, G | 1 |
| Christenfeld, R | 1 |
| Hüller, H | 1 |
| Marin, J | 1 |
| Chiner, E | 1 |
| Franco, J | 1 |
| Borras, R | 1 |
| Koike, T | 1 |
| Kurasawa, K | 1 |
| Yamazaki, S | 1 |
| Matsumura, R | 1 |
| Yoshida, H | 1 |
| Yoshida, S | 1 |
| Ohshima, H | 1 |
| Pyrig, LA | 1 |
| Rudenko, AV | 2 |
| Nikonova, NA | 1 |
| Kudriavskaia, VM | 2 |
| Saksonov, SI | 1 |
| Meshcheriakova, EV | 1 |
| Baras, ES | 1 |
| Beker, OM | 1 |
| Mourad, G | 1 |
| Legendre, C | 1 |
| Argiles, A | 1 |
| Bonardet, A | 1 |
| Mion, C | 1 |
| Pyrit, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma[NCT00825149] | Phase 1 | 137 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease.[NCT00517530] | Phase 1/Phase 2 | 134 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Randomized, Controlled Trial Evaluating the Role of ImmuKnow® in the Management of Immunosuppressants Regarding Opportunistic Infections and Acute Rejection in the Renal Transplant Patient[NCT01424345] | Phase 4 | 40 participants (Anticipated) | Interventional | 2011-12-31 | Terminated (stopped due to The PI is relocating to another State/ another hospital) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood samples were taken on Day 1 (pre-infusion, end of infusion, 3-6 hours post-infusion) of Cycle 1. Nonlinear mixed-effects modeling (with NONMEM software) was used to analyze the pooled samples for dose-concentration-time data of obinutuzumab. (NCT00517530)
Timeframe: Day 1 of Cycle 1
| Intervention | µm/ml*day (Geometric Mean) |
|---|---|
| 400 mg - Phase I, NHL | 459 |
| 800 mg - Phase I, NHL | 993 |
| 1200 mg - Phase I, NHL | 1057 |
| 2000 mg - Phase I, NHL | 146 |
Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as >= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A >= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of < 1.0 cm must increase by >= 50% and to a size of 1.5×1.5 cm or > 1.5 cm in the longest axis. (2) Appearance of any new lesion > 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation. (NCT00517530)
Timeframe: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
| Intervention | days (Median) |
|---|---|
| Phase II, iNHL | 523 |
| Phase II, aNHL | 298 |
| Phase II, CLL | 272.5 |
EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first. (NCT00517530)
Timeframe: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
| Intervention | participants (Number) |
|---|---|
| 400/400 mg - Phase II, iNHL | 5 |
| 1600/800 mg - Phase II, iNHL | 6 |
| 400/400 mg - Phase II, aNHL | 2 |
| 1600/800 mg - Phase II, aNHL | 3 |
| 1000/1000 mg - Phase II, CLL | 4 |
Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab. (NCT00517530)
Timeframe: Baseline to 28 days after the last infusion of obinutuzumab (up to 6 months)
| Intervention | percentage of participants (Number) |
|---|---|
| 50/100 mg - Phase I, NHL | 0 |
| 100/200 mg - Phase I, NHL | 0 |
| 200/400 mg - Phase I, NHL | 0 |
| 400/800 mg - Phase I, NHL | 0 |
| 800/1200 mg - Phase I, NHL | 0 |
| 1200/2000 mg - Phase I, NHL | 0 |
| 1600/800 mg - Phase I, NHL | 0 |
| 400/800 mg - Phase I, CLL | 0 |
| 800/1200 mg - Phase I, CLL | 0 |
| 1200/2000 mg - Phase I, CLL | 0 |
| 1000/1000 mg - Phase I, CLL | 0 |
Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR) (NCT00517530)
Timeframe: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
| Intervention | percentage of participants (Number) |
|---|---|
| 400/400 mg - Phase II, iNHL | 33.3 |
| 1600/800 mg - Phase II, iNHL | 63.6 |
| 400/400 mg - Phase II, aNHL | 23.8 |
| 1600/800 mg - Phase II, aNHL | 36.8 |
| 1000/1000 mg - Phase II, CLL | 30.0 |
A PR was defined as a >=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by >=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites. (NCT00517530)
Timeframe: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
| Intervention | percentage of participants (Number) |
|---|---|
| 400/400 mg - Phase II, iNHL | 22.2 |
| 1600/800 mg - Phase II, iNHL | 40.9 |
| 400/400 mg - Phase II, aNHL | 9.5 |
| 1600/800 mg - Phase II, aNHL | 21.1 |
| 1000/1000 mg - Phase II, CLL | 25.0 |
PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as >= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A >= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of < 1.0 cm must increase by >= 50% and to a size of 1.5×1.5 cm or > 1.5 cm in the longest axis. (2) Appearance of any new lesion > 1 cm in the short axis. (4) A new site that is positron emission tomography (PET)-positive with histological confirmation. (NCT00517530)
Timeframe: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
| Intervention | days (Median) |
|---|---|
| 400/400 mg - Phase II, iNHL | 182 |
| 1600/800 mg - Phase II, iNHL | 361 |
| 400/400 mg - Phase II, aNHL | 78 |
| 1600/800 mg - Phase II, aNHL | 83 |
| 1000/1000 mg - Phase II, CLL | 324 |
(NCT00517530)
Timeframe: at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)
| Intervention | micrograms/mL (Geometric Mean) | ||
|---|---|---|---|
| Cycle 1 Day 1 (n=3,3,3,0) | Cycle 1 Day 8 (n=0,0,3,3) | Cycle 8 (n=3,3,3,4) | |
| 1200 mg - Phase I, CLL | 307 | 437 | 741 |
| 2000 mg - Phase I, CLL | NA | 735 | 1730 |
| 400 mg - Phase I, CLL | 216 | NA | 485 |
| 800 mg - Phase I, CLL | 210 | NA | 573 |
Obinutuzumab serum pharmacokinetic (PK) parameters in NHL participants following ascending doses. (NCT00517530)
Timeframe: at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)
| Intervention | µm/ml*day (Geometric Mean) | ||
|---|---|---|---|
| Cycle 1 Day 1 (n=4,6,6,0) | Cycle 1 Day 8 (n=0,4,6,6) | Cycle 8 (n=0,5,5,5) | |
| 1200 mg - Phase I, NHL | 307 | 449 | 1070 |
| 2000 mg - Phase I, NHL | NA | 714 | 1380 |
| 400 mg - Phase I, NHL | 134 | NA | NA |
| 800 mg - Phase I, NHL | 234 | 367 | 698 |
A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL. (NCT00517530)
Timeframe: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| CR | CRu | CRi | |
| 1000/1000 mg - Phase II, CLL | 5.0 | NA | 0.0 |
| 1600/800 mg - Phase II, aNHL | 15.8 | 0.0 | NA |
| 1600/800 mg - Phase II, iNHL | 13.6 | 9.1 | NA |
| 400/400 mg - Phase II, aNHL | 9.5 | 4.8 | NA |
| 400/400 mg - Phase II, iNHL | 5.6 | 5.6 | NA |
Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator. (NCT00517530)
Timeframe: by Cutoff Date: 25 November 2013 (within 4 years, 2 months)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Best overall response | Complete response | Partial response | |
| Retreated Participants | 62 | 23 | 38 |
B-cell depletion was defined in two ways: definition 1 - decrease below 5% baseline level and definition 2 - decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 - return to at least 50% of baseline level and definition 2 - return to at least 0.08 x 109/L. (NCT00517530)
Timeframe: by the end of Phase II (within 3 years, 4 months)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| within 6 months (n=11,19,11,12,13) | within 9 months (n=8,17,6,5,10) | within 12 months (n=5,16,4,5,9) | within 18 months (n=4,13,3,3,8) | within 24 months (n=3,10,2,3,5) | after 24 months (n=3,4,1,2,0) | |
| 1000/1000 mg - Phase II, CLL | 3 | 0 | 3 | 2 | 2 | 0 |
| 1600/800 mg - Phase II, aNHL | 0 | 1 | 0 | 1 | 0 | 1 |
| 1600/800 mg - Phase II, iNHL | 0 | 0 | 2 | 1 | 2 | 0 |
| 400/400 mg - Phase II, aNHL | 0 | 0 | 1 | 0 | 1 | 0 |
| 400/400 mg - Phase II, iNHL | 0 | 0 | 0 | 0 | 2 | 1 |
12 reviews available for prednisolone and Opportunistic Infections
| Article | Year |
|---|---|
[Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 3. Opportunistic infections].
Topics: Antirheumatic Agents; Aspergillosis; Biological Factors; Collagen Diseases; Cryptococcosis; Cytomega | 2013 |
[Therapy and prognosis of medium and small vessel vasculitis].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cyclophosphamide; Drug Therapy, Combinat | 2014 |
Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biological Therapy; Humans; Opportunistic Infection | 2012 |
[Collagen diseases with opportunistic infections].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheu | 2004 |
Aspergillus endocarditis in a native valve after amphotericin B treatment.
Topics: Amphotericin B; Anti-Infective Agents; Aspergillosis; Aspergillus fumigatus; Candidiasis; Drug Resis | 2004 |
[Corticosteroids for treatment of rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Drug Resistance; Femur Head Necrosis; Glucocorticoids; Humans; Methylpredniso | 2005 |
[Pneumocystis carinii pneumonia in patients with connective tissue diseases].
Topics: Anti-Infective Agents; Connective Tissue Diseases; Drug Therapy, Combination; Humans; Molecular Diag | 2002 |
Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review.
Topics: Adult; Cryptococcosis; Cryptococcus neoformans; Drug Administration Schedule; Epidemiologic Methods; | 2007 |
Cutaneous alternariosis: role of corticosteroid-induced cutaneous fragility.
Topics: Aged; Alternaria; Biopsy, Needle; Dermatomycoses; Dermatomyositis; Female; Follow-Up Studies; Glucoc | 1996 |
[Immunodeficiency induced by immunosuppressive agents].
Topics: Azathioprine; Cyclophosphamide; Cyclosporine; Diagnosis, Differential; Humans; Immunologic Deficienc | 2000 |
[Pulmonary nocardiosis associated with nephrotic syndrome].
Topics: Aged; Humans; Male; Nephrotic Syndrome; Nocardia asteroides; Nocardia Infections; Opportunistic Infe | 2001 |
Case report. Phaeohyphomycosis caused by Phialophora verrucosa developed in a patient with non-HIV acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents; Dermatomycoses; Fatal Outcome; Female; | 2002 |
4 trials available for prednisolone and Opportunistic Infections
| Article | Year |
|---|---|
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Ag | 2016 |
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Ag | 2016 |
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Ag | 2016 |
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Ag | 2016 |
[Effects of fluconazole on onychomycosis in the patients with collagen diseases].
Topics: Adult; Collagen Diseases; Female; Fluconazole; Humans; Male; Middle Aged; Onychomycosis; Opportunist | 1995 |
Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation.
Topics: Adrenal Cortex Hormones; Biopsy; Cyclosporine; Drug Therapy, Combination; Female; Gastrointestinal D | 2000 |
Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.
Topics: Adrenal Cortex Hormones; Cyclosporine; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug The | 2001 |
84 other studies available for prednisolone and Opportunistic Infections
| Article | Year |
|---|---|
Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report.
Topics: Colitis, Ulcerative; Cytomegalovirus Infections; Fluconazole; Humans; Inflammatory Bowel Diseases; M | 2023 |
A Decade of Varicella Screening Within a Paediatric Inflammatory Bowel Disease Population.
Topics: Anti-Inflammatory Agents; Antibodies, Viral; Chickenpox; Child; Female; Hospitalization; Humans; Imm | 2020 |
Recurrent Phaeohyphomycosis due to Phaeoacremonium alvesii Identified with Internal Transcribed Spacer and Beta-tubulin Gene Sequencing.
Topics: Aged, 80 and over; Antifungal Agents; Ascomycota; Dermatomycoses; DNA, Fungal; DNA, Ribosomal Spacer | 2020 |
[Neurological symptoms in a patient on anti-TNF therapy, methotrexate and prednisolone for rheumatoid arthritis].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Brain; Diagnosis, Differential; Drug Therapy, Com | 2020 |
Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
Topics: Adult; Aged; Azathioprine; Basiliximab; Drug Administration Schedule; Female; Glucocorticoids; Graft | 2020 |
Atypical presentation of a central nervous system aspergillosis in a peripheral T cell lymphoma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brown-Sequard Syndrome; Cyclophos | 2020 |
Induction of Severe Chronic Hyperplastic Candidiasis in Rat by Opportunistic Infection of C. albicans through Combination of Diabetes and Intermittent Prednisolone Administration.
Topics: Animals; Candida albicans; Candidiasis; Carcinogenesis; Diabetes Mellitus, Experimental; Drug Admini | 2017 |
[Infections during glucocorticoid use].
Topics: Animals; Comorbidity; Glucocorticoids; Humans; Medical History Taking; Opportunistic Infections; Pne | 2018 |
[Complete elimination of cytomegalovirus without antiviral therapy after systemic mesenchymal stromal cell transplantation in a patient with ulcerative colitis (a clinical case)].
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Viral; Biopsy; Colitis, Ulcerative; Cytomegalovirus; Cy | 2012 |
T cell non-Hodgkin's lymphoma with colesional mucormycosis presenting as palatal perforation: a case report.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2012 |
Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; An | 2014 |
[Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia].
Topics: Amikacin; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Clarithromycin; Cyclophosphamide; Hu | 2014 |
The development of pulmonary aspergillosis and pneumothorax in a patient with neutropenic systemic lupus erythematosus and successful treatment of the first case.
Topics: Anti-Inflammatory Agents; Antifungal Agents; Aspergillus fumigatus; Drainage; Female; Humans; Lupus | 2014 |
Catastrophic gastrointestinal complication of systemic immunosuppression.
Topics: Aged; Antiviral Agents; Biopsy; Cyclophosphamide; Cytomegalovirus Infections; Duodenitis; Endoscopy, | 2015 |
Efficacy and Safety of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplantation: A Japanese Multicenter Study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Basiliximab; Case-Control Studies; Cyclosporine; Cytome | 2016 |
Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli.
Topics: Animals; Antimicrobial Cationic Peptides; Drug Therapy, Combination; Escherichia coli Infections; Fe | 2017 |
Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus.
Topics: Adult; Case-Control Studies; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; Humans; Immun | 2009 |
[Acquired hemophilia complicated with multiple muscle abscess by Nocardia].
Topics: Abscess; Aged, 80 and over; Biopsy, Fine-Needle; Cyclosporine; Hemophilia A; Humans; Immunocompromis | 2009 |
[MRSA infection of the hand in immunodeficient patients].
Topics: Aged; Amputation, Surgical; Anti-Bacterial Agents; Antineoplastic Agents, Hormonal; Combined Modalit | 2009 |
[A case of disseminated nocardiosis followed by pneumocystis pneumonia in a patient prescribed corticosteroid and cyclosporin A and having elevated blood (1-->3)-beta-D-glucan].
Topics: Aged; beta-Glucans; Cyclosporine; Humans; Male; Nocardia Infections; Opportunistic Infections; Pemph | 2009 |
Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes.
Topics: Adenosine Triphosphate; Adult; Aged; Biopsy; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; | 2010 |
Development of Candida albicans colitis in a child undergoing steroid therapy for ulcerative colitis.
Topics: Adolescent; Betamethasone; Candida albicans; Candidiasis; Colitis; Colitis, Ulcerative; Glucocortico | 2010 |
[Unilateral odynophagia in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cooperative Behavior; Deglutition Disorders; Diagnosis, | 2011 |
Young male with systemic lupus erythematosus presenting with sensorineural deafness with immune suppression induced miliary tuberculosis.
Topics: Adult; Antineoplastic Agents; Antitubercular Agents; Biopsy; Hearing Loss, Sensorineural; Humans; Im | 2011 |
Cryptococcal cellulitis in a patient with bullous pemphigoid.
Topics: Aged; Antifungal Agents; Cellulitis; Cryptococcosis; Cryptococcus neoformans; Dermatomycoses; Glucoc | 2013 |
A possible novel mechanism of opportunistic infection in systemic lupus erythematosus, based on a case of toxoplasmic encephalopathy.
Topics: Adult; Animals; Anti-Infective Agents; Antibodies, Protozoan; Cerebral Cortex; Drug Combinations; Fe | 2002 |
Disseminated candidiasis following prednisolone therapy in systemic lupus erythematosus.
Topics: Anti-Inflammatory Agents; Candidiasis; Child; Humans; Lupus Erythematosus, Systemic; Male; Multiple | 2002 |
PCR-aided diagnosis of fungal chorioretinitis following ingestion of traditional Chinese medication.
Topics: Aged; Amphotericin B; Antifungal Agents; Chorioretinitis; DNA, Fungal; Drug Therapy, Combination; Dr | 2002 |
[Functional asplenia after severe varicella zoster-infection diagnosis by colour Doppler ultrasound].
Topics: Adult; Atrophy; Azathioprine; Crohn Disease; Drug Therapy, Combination; Follow-Up Studies; Herpes Zo | 2003 |
Cerebral toxoplasmosis after autologous peripheral blood stem cell transplantation.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 2003 |
An overwhelming pulmonary fungus ball in a systemic lupus erythematosus patient.
Topics: Adult; Anti-Inflammatory Agents; Aspergillosis; Diagnosis, Differential; Female; Humans; Lung; Lupus | 2003 |
[A case of left hemiplegia following erythema, fever, and gastrointestinal bleeding].
Topics: Adult; Anti-Inflammatory Agents; Cyclophosphamide; Diagnosis, Differential; Disseminated Intravascul | 2004 |
Disseminated cutaneous infection with Mycobacterium chelonae in a patient with steroid-dependent rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Fatal Outcome; Glucocorticoids; Humans; Immunocompromised Host; Male; Middle | 2004 |
[Fatal opportunistic infection following disappearance of antibodies by immunosuppressive therapy in a patient with acquired factor VIII inhibitor].
Topics: Aged; Aged, 80 and over; Autoantibodies; Cyclophosphamide; Cyclosporine; Cytomegalovirus Infections; | 2004 |
Cerebral toxoplasmosis in a patient with common variable immunodeficiency.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Protozoan; Antiprotozoal Agents; Biopsy; Brain; Central N | 2004 |
Fatal fulminant legionnaires' disease in a patient with severe erythodermic psoriasis treated with infliximab after long-term steroid therapy.
Topics: Antibodies, Monoclonal; Dermatologic Agents; Fatal Outcome; Glucocorticoids; Humans; Infliximab; Leg | 2005 |
[A case of chronic renal failure complicated with tuberculous meningitis successfully diagnosed by nested polymerase chain reaction (PCR)].
Topics: Adult; DNA, Bacterial; Female; Glomerulonephritis; Humans; Immunocompromised Host; Kidney Failure, C | 2005 |
A case of tuberculous meningoencephalitis in a patient with Behçet's disease.
Topics: Adult; Antitubercular Agents; Behcet Syndrome; Colchicine; Cyclosporine; DNA, Bacterial; Drug Therap | 2006 |
[Pulmonary nocardiosis complicated with multiple brain abscess].
Topics: Anemia, Hemolytic, Autoimmune; Brain Abscess; Female; Humans; Lung Diseases; Middle Aged; Nocardia I | 2005 |
Cytomegalovirus-induced interstitial pneumonitis in a patient with dermatomyositis.
Topics: Adult; Antiviral Agents; Azathioprine; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; De | 2006 |
Fatal varicella infection in a girl with systemic lupus erythematosus after oral acyclovir prophylaxis.
Topics: Acyclovir; Adolescent; Antiviral Agents; Aspergillosis; Azathioprine; Brain; Chickenpox; Disseminate | 2006 |
[Effective treatment for a methotrexate-associated lymphoproliferative disorder with R-CHOP following administration of rituximab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2005 |
[Pneumocystis jiroveci pneumonia as a complication of glucocorticoid therapy for interstitial pneumonia].
Topics: Aged; Anti-Infective Agents; Drug Administration Schedule; Female; Glucocorticoids; Humans; Lung Dis | 2005 |
[Gas gangrene with ulcerative colitis under immunosuppressive therapy: report of a case].
Topics: Adult; Amputation, Surgical; Buttocks; Colitis, Ulcerative; Debridement; Diagnosis, Differential; Fa | 2006 |
[Pulmonary infection of Pneumocystis carinii and Cytomegalo virus in the treatment of cholesterol crystal embolism].
Topics: Angioplasty, Balloon, Coronary; Cytomegalovirus Infections; Embolism, Cholesterol; Humans; Male; Mid | 2006 |
Clinical features, prognostic and risk factors of central nervous system infections in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Central Nervous System Infections; China; Cohort Studies; Dose-Response Relations | 2007 |
[Radiological findings in initial pulmonary alveolar proteinosis detected in the post-treatment course of nocardiosis].
Topics: Anemia, Hemolytic, Autoimmune; Female; Humans; Middle Aged; Nocardia Infections; Opportunistic Infec | 2006 |
[Successful treatment by voliconazole for pulmonary and adductor magnus muscle aspergillosis induced by immunosuppressive therapy for hypersensitivity pneumonia].
Topics: Aged; Alveolitis, Extrinsic Allergic; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Cyclo | 2006 |
Cytomegalovirus infection complicating immunosuppressive therapy for dermatomyositis.
Topics: Aged; Antiviral Agents; Cyclophosphamide; Cytomegalovirus Infections; Dermatomyositis; Fatal Outcome | 2006 |
Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin.
Topics: Aged; Anemia; Antibodies; Chronic Disease; Cyclophosphamide; Darbepoetin alfa; Erythropoietin; Fatal | 2007 |
Soft tissue manifestations of mycobacterial infection in patients with rheumatic diseases.
Topics: Adult; Fatal Outcome; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; | 2007 |
[A case of pulmonary nocardiosis cured by early sulfamethoxazole-trimethoprim therapy].
Topics: Anti-Infective Agents; Humans; Lung Diseases; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; | 2007 |
Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Facial Neoplasms; Female; Hemangioma; Humans; | 2007 |
[Atypical ocular toxoplasmosis with concomitant ocular reactivation of varicella-zoster virus and cytomegalovirus in an immunocompromised host].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blindness; Chlorambucil; Chorioretinitis; Como | 2008 |
[Mycotic retrobulbar neuritis].
Topics: Aged; Anemia, Aplastic; Diagnosis, Differential; Female; Humans; Lymphoma, Non-Hodgkin; Opportunisti | 1994 |
Nephrotic syndrome in the elderly--clinicopathological study.
Topics: Aged; Female; Humans; Kidney; Male; Middle Aged; Nephrotic Syndrome; Opportunistic Infections; Predn | 1994 |
Disseminated subcutaneous Nocardia asteroides abscesses in a patient after bone marrow transplantation.
Topics: Abscess; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marro | 1993 |
Induction toxicity of a modified Memorial Sloan-Kettering-New York II Protocol in children with relapsed acute lymphoblastic leukemia: a single institution study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Daunorubicin; | 1996 |
[Pneumocystis carinii and aspergillus pneumonia in immunosuppression in rapidly progressing glomerulonephritis of the anti-glomerular basement membrane type].
Topics: Adult; Aspergillosis; Autoimmune Diseases; Basement Membrane; Cyclophosphamide; Drug Therapy, Combin | 1996 |
[A case of allergic bronchopulmonary aspergillosis following active pulmonary tuberculosis].
Topics: Aged; Anti-Inflammatory Agents; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Aspergi | 1996 |
[Invasive disseminated aspergillosis in combined immunosuppressive therapy in systemic lupus erythematosus].
Topics: Aged; Aspergillosis; Cyclophosphamide; Drug Therapy, Combination; Fatal Outcome; Female; Fungemia; H | 1996 |
An unusual complication of immunosuppressive therapy in inflammatory bowel disease.
Topics: Aged; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antim | 1997 |
[Recurrent fever in a patient treated with immunosuppressive therapy for Takayasu arteritis].
Topics: Abdominal Abscess; Adult; Cyclophosphamide; Diagnosis, Differential; Dose-Response Relationship, Dru | 1997 |
Immunosuppression and incidence of opportunistic pneumonias after liver transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Azathioprine; Child; Child, Preschool; Cyclosporine | 1998 |
Cardiac transplant-related cutaneous malignancies in an Australian recipient: immunosuppression, friend or foe?
Topics: Adult; Australia; Azathioprine; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cy | 1998 |
Rhodococcus equi lung abscess complicating Evan's syndrome treated with corticosteroid.
Topics: Actinomycetales Infections; Aged; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Drug Therapy | 1998 |
Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Cytomegalovirus Infections; Female; Glucocorticoids; Gra | 2000 |
[A case of pityriasis rubra pilaris associated with unclassified connective tissue disease and sepsis in clinical course].
Topics: Adult; Antibodies, Antinuclear; Bacteremia; Biomarkers; Carrier State; Connective Tissue Diseases; E | 1998 |
[A case of systemic lupus erythematosus with pure red cell aplasia possibly caused by persistent infection of human parvovirus B 19].
Topics: Aged; Antiphospholipid Syndrome; Female; Humans; Immunocompromised Host; Lupus Erythematosus, System | 1998 |
Strongyloides hyperinfection syndrome--an unappreciated opportunistic infection.
Topics: Animals; Follow-Up Studies; Glomerulonephritis; Humans; Male; Middle Aged; Opportunistic Infections; | 2000 |
Sarcoidosis and opportunistic infections.
Topics: Aged; Anti-Inflammatory Agents; Biopsy; Diagnosis, Differential; Histoplasmosis; Humans; Immunity, C | 2001 |
Early onset Pneumocystis carinii pneumonia after allogeneic peripheral blood stem cell transplantation.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modal | 2001 |
Pulmonary nocardiosis in a patient treated with corticosteroid therapy.
Topics: Aged; Arthritis, Rheumatoid; Cilastatin; Cilastatin, Imipenem Drug Combination; Diagnosis, Different | 2002 |
Pneumonia and pneumonitis in childhood malignancy.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; C | 1992 |
[Cryptococcal meningoencephalitis following immunosuppressive therapy].
Topics: Adult; Azathioprine; Brain; Cryptococcus neoformans; Female; Humans; Immune Tolerance; Lupus Erythem | 1992 |
Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone.
Topics: Arthritis, Rheumatoid; Cytomegalovirus Infections; Humans; Male; Methotrexate; Middle Aged; Opportun | 1991 |
Opportunistic Listeria pericardial effusion.
Topics: Arthritis, Rheumatoid; Carcinoma, Squamous Cell; Female; Humans; Listeriosis; Middle Aged; Opportuni | 1990 |
[Results of conversion from conventional immunosuppressive therapy to cyclosporin A in complications following kidney transplantation].
Topics: Adolescent; Adult; Azathioprine; Creatinine; Cyclosporins; Female; Follow-Up Studies; Graft Rejectio | 1990 |
Trichosporon beigelii pneumonia in a neutropenic patient.
Topics: Agranulocytosis; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Lung Diseases, Fungal; Mal | 1989 |
[Pulmonary opportunistic infections in patients with autoimmune diseases].
Topics: Adult; Aged; Autoimmune Diseases; Female; Humans; Isoniazid; Lung Diseases, Fungal; Male; Middle Age | 1989 |
[Dynamics of Mycoplasma infection in patients with glomerulo- nephritis during pathogenetic therapy].
Topics: Cyclophosphamide; Drug Resistance, Microbial; Glomerulonephritis; Humans; Immune Tolerance; Mycoplas | 1989 |
[Corticosteroid tuberculosis].
Topics: Asthma; Bronchopneumonia; Female; Humans; Immune Tolerance; Male; Middle Aged; Opportunistic Infecti | 1988 |
Triple drug immunosuppression (cyclosporine, azathioprine and low-dose prednisolone): a safe and effective regimen in first-cadaver kidney transplantation.
Topics: Azathioprine; Bacterial Infections; Cadaver; Cyclosporins; Drug Therapy, Combination; Graft Rejectio | 1987 |
[Complications caused by fungi of the genus Candida in patients with glomerulonephritis during pathogenetic therapy].
Topics: Candidiasis; Cyclophosphamide; Glomerulonephritis; Humans; Immunosuppressive Agents; Opportunistic I | 1988 |